KR102618947B1 - 뇌 질환을 치료하기 위한 방법 및 조성물 - Google Patents

뇌 질환을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102618947B1
KR102618947B1 KR1020177020915A KR20177020915A KR102618947B1 KR 102618947 B1 KR102618947 B1 KR 102618947B1 KR 1020177020915 A KR1020177020915 A KR 1020177020915A KR 20177020915 A KR20177020915 A KR 20177020915A KR 102618947 B1 KR102618947 B1 KR 102618947B1
Authority
KR
South Korea
Prior art keywords
aav
mice
rhes
subject
mtorc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177020915A
Other languages
English (en)
Korean (ko)
Other versions
KR20170098931A (ko
Inventor
비벌리 엘. 데이비슨
존 에이치. 리
Original Assignee
유니버시티 오브 아이오와 리써치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 아이오와 리써치 파운데이션 filed Critical 유니버시티 오브 아이오와 리써치 파운데이션
Publication of KR20170098931A publication Critical patent/KR20170098931A/ko
Application granted granted Critical
Publication of KR102618947B1 publication Critical patent/KR102618947B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020177020915A 2014-12-30 2015-12-30 뇌 질환을 치료하기 위한 방법 및 조성물 Active KR102618947B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098085P 2014-12-30 2014-12-30
US62/098,085 2014-12-30
PCT/US2015/068034 WO2016109649A1 (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Publications (2)

Publication Number Publication Date
KR20170098931A KR20170098931A (ko) 2017-08-30
KR102618947B1 true KR102618947B1 (ko) 2023-12-27

Family

ID=56285031

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177020915A Active KR102618947B1 (ko) 2014-12-30 2015-12-30 뇌 질환을 치료하기 위한 방법 및 조성물

Country Status (12)

Country Link
US (1) US11612641B2 (https=)
EP (1) EP3240577B1 (https=)
JP (1) JP6782701B2 (https=)
KR (1) KR102618947B1 (https=)
CN (1) CN107405414A (https=)
AU (1) AU2015374043B2 (https=)
BR (1) BR112017013674A2 (https=)
CA (1) CA2971687C (https=)
ES (1) ES2962439T3 (https=)
SG (1) SG11201704829QA (https=)
WO (1) WO2016109649A1 (https=)
ZA (1) ZA201704327B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016109649A1 (en) 2014-12-30 2016-07-07 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
WO2018132791A1 (en) * 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
WO2006116716A2 (en) 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
KR101286870B1 (ko) * 2009-11-30 2013-07-16 (주)아모레퍼시픽 황기 추출물을 포함하는 대사 촉진 조성물
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center SIMULTANEOUS ACTIVATION OF MTOR AND STAT3 PATHS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
WO2013116691A1 (en) 2012-02-02 2013-08-08 The Washington University Methods for improving muscle strength
KR101626526B1 (ko) 2014-10-30 2016-06-02 경북대학교 산학협력단 ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물
WO2016109649A1 (en) 2014-12-30 2016-07-07 University Of Iowa Research Foundation Methods and compositions for treating brain diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2013. 43rd Annual Meeting of the Society-For-Neuroscience.(Poster #306.05)(2013.11.11.)*
Journal of Biological Chemistry. 2006. Vol.281, No.29, pp.19793-19797.*
Molecular Therapy. 2012. Vol.20, No.2, pp.275-286.*

Also Published As

Publication number Publication date
US11612641B2 (en) 2023-03-28
EP3240577A1 (en) 2017-11-08
EP3240577A4 (en) 2018-07-25
CN107405414A (zh) 2017-11-28
HK1245127A1 (en) 2018-08-24
CA2971687A1 (en) 2016-07-07
US20180000907A1 (en) 2018-01-04
WO2016109649A1 (en) 2016-07-07
NZ733014A (en) 2024-05-31
ZA201704327B (en) 2025-02-26
JP6782701B2 (ja) 2020-11-11
CA2971687C (en) 2024-05-28
EP3240577B1 (en) 2023-07-05
JP2018502112A (ja) 2018-01-25
KR20170098931A (ko) 2017-08-30
ES2962439T3 (es) 2024-03-19
SG11201704829QA (en) 2017-07-28
BR112017013674A2 (pt) 2018-02-06
AU2015374043B2 (en) 2021-05-13
AU2015374043A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
KR102618947B1 (ko) 뇌 질환을 치료하기 위한 방법 및 조성물
US20240226203A9 (en) Compositions and methods of treating huntington's disease
US20230295663A1 (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
US20220333131A1 (en) Modulatory polynucleotides
AU2018352236B2 (en) Treatment of amyotrophic lateral sclerosis (ALS)
US11155817B2 (en) Therapeutic for treatment of diseases including the central nervous system
JP2006521825A (ja) ｒＡＡＶ導入を高めるための化合物および方法
US20240343768A1 (en) Gene therapy for tuberous sclerosis
CN112955169A (zh) 用于肌萎缩性侧索硬化疗法中的胆固醇24-水解酶的表达载体
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
EP3962514A1 (en) Methods and compositions involving tert activating therapies
KR20240150772A (ko) 폴리q 질환 치료를 위한 치료 인자
HK1245127B (en) Therapeutic agent that activates mtorc1 function for use in treating huntington's disease
WO2025015328A2 (en) Increasing nfe2l1 activity or expression as therapy for eye disorders
JP2022531177A (ja) 神経変性障害を治療するための方法
HK40052708B (zh) 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体
HK40052708A (zh) 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170726

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230313

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230925

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration